Article Correctness Is Author's Responsibility: PharmaMar starts clinical studies with a new compound -PM14- in patients with solid tumors

(Pharmamar) With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (MSE:PHM) announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors.
Posted in Uncategorized